Prognosis of impulse control disorders in Parkinson’s disease: a prospective controlled study
Thomas Wirth
(1, 2, 3)
,
Thibaut Goetsch
(4)
,
Jean-Christophe Corvol
(5)
,
Emmanuel Roze
(5)
,
Louise-Laure Mariani
(5)
,
Marie Vidailhet
(5)
,
David Grabli
(5)
,
Luc Mallet
(5, 6)
,
Antoine Pelissolo
(7, 8)
,
Olivier Rascol
(9, 10)
,
Christine Brefel-Courbon
(9)
,
Fabienne Ory-Magne
(9)
,
Christophe Arbus
(11)
,
Samir Bekadar
(5)
,
Pierre Krystkowiak
(12, 13)
,
Ana Marques
(14, 15)
,
Michel Llorca
(16)
,
Paul Krack
(17)
,
Anna Castrioto
(18, 19)
,
Valérie Fraix
(18, 19)
,
David Maltete
(20)
,
Luc Defebvre
(21)
,
Alexandre Kreisler
(21)
,
Jean-Luc Houeto
(22)
,
Christine Tranchant
(1, 2, 3)
,
Nicolas Meyer
(4)
,
Mathieu Anheim
(1, 2, 3)
1
Service de Neurologie [Strasbourg]
2 IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire
3 FMTS - Fédération de Médecine Translationnelle de Strasbourg
4 HUS - Les Hôpitaux Universitaires de Strasbourg
5 ICM - Institut du Cerveau = Paris Brain Institute
6 Département de Psychiatrie
7 U955 Inserm - UPEC - IMRB - "Neuropsychiatrie translationnelle" [Créteil]
8 CHU Henri Mondor [Créteil]
9 Département Neurologie [CHU Toulouse]
10 CIC 1436 - Centre d'investigation clinique de Toulouse
11 Pôle Psychiatrie [CHU Toulouse]
12 Service de neurologie [Amiens]
13 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
14 INP Clermont Auvergne - Institut national polytechnique Clermont Auvergne
15 IP - Institut Pascal
16 Service Psychiatrie Adulte [CHU Clermont-Ferrand]
17 Inselspital - Bern University Hospital [Berne]
18 Pôle Psychiatrie et Neurologie [Grenoble]
19 GIN - [GIN] Grenoble Institut des Neurosciences
20 Service de neurologie [Rouen]
21 Service de neurologie et pathologie du mouvement
22 Service de neurologie [Poitiers]
2 IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire
3 FMTS - Fédération de Médecine Translationnelle de Strasbourg
4 HUS - Les Hôpitaux Universitaires de Strasbourg
5 ICM - Institut du Cerveau = Paris Brain Institute
6 Département de Psychiatrie
7 U955 Inserm - UPEC - IMRB - "Neuropsychiatrie translationnelle" [Créteil]
8 CHU Henri Mondor [Créteil]
9 Département Neurologie [CHU Toulouse]
10 CIC 1436 - Centre d'investigation clinique de Toulouse
11 Pôle Psychiatrie [CHU Toulouse]
12 Service de neurologie [Amiens]
13 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
14 INP Clermont Auvergne - Institut national polytechnique Clermont Auvergne
15 IP - Institut Pascal
16 Service Psychiatrie Adulte [CHU Clermont-Ferrand]
17 Inselspital - Bern University Hospital [Berne]
18 Pôle Psychiatrie et Neurologie [Grenoble]
19 GIN - [GIN] Grenoble Institut des Neurosciences
20 Service de neurologie [Rouen]
21 Service de neurologie et pathologie du mouvement
22 Service de neurologie [Poitiers]
Thomas Wirth
- Fonction : Auteur
- PersonId : 1161314
- ORCID : 0000-0002-4427-5765
Jean-Christophe Corvol
- Fonction : Auteur
- PersonId : 981427
- ORCID : 0000-0001-7325-0199
- IdRef : 087943492
Louise-Laure Mariani
- Fonction : Auteur
- PersonId : 1106258
- IdHAL : louise-laure-mariani-halid
- ORCID : 0000-0002-2365-1223
- IdRef : 249283646
Marie Vidailhet
- Fonction : Auteur
- PersonId : 758783
- ORCID : 0000-0002-2409-9143
- IdRef : 074466208
David Grabli
- Fonction : Auteur
- PersonId : 1012469
- ORCID : 0000-0001-6798-4567
- IdRef : 076385116
Olivier Rascol
- Fonction : Auteur
- PersonId : 938353
- ORCID : 0000-0002-1410-6397
- IdRef : 084129980
Christine Brefel-Courbon
- Fonction : Auteur
- PersonId : 1356183
- ORCID : 0009-0002-7262-2338
- IdRef : 16754439X
Fabienne Ory-Magne
- Fonction : Auteur
- PersonId : 988022
- ORCID : 0000-0001-6179-4500
- IdRef : 061282650
Résumé
Background: The long-term prognosis of impulsive compulsive disorders (ICD) remains poorly studied in Parkinson's disease (PD).
Objective: Evaluating the natural history of ICD and its impact on PD symptoms including cognition and treatment adjustments.
Materials and methods: We assessed PD patients at baseline (BL) with (BL-ICD+) or without (BL-ICD-) ICD despite dopamine agonist (DA) exposure of > 300 mg levodopa-equivalent daily dose for > 12 months at baseline and after more than two years of follow-up. ICD were assessed using the Ardouin's Scale of Behaviors in PD (ASBPD), cognition using the Mattis scale, and PD symptoms using the UPDRS score. Treatment adjustments, DA withdrawal-associated symptoms, and ICDs social consequences were recorded.
Results: 149 patients were included (78 cases and 71 controls), mean duration of follow-up was 4.4 ± 1 years. At baseline, psychiatric disorders were more common among BL-ICD + (42.3 vs 12.3% among BL-ICD-, p < 0.01). At follow-up, 53.8% of BL-ICD + were not ICD-free while 21.1% of BL-ICD- had developed ICD. BL-ICD + more frequently experienced akinesia (21.8 vs 8.5%, p = 0.043) and rigidity worsening (11.5 vs 1.4%, p = 0.019) following therapeutic modifications. Decision to decrease > 50% DA doses (12.8 vs 1.4%, p = 0.019) or to withdraw DA (19.2 vs 5.6%, p = 0.025) was more frequently considered among BL-ICD+ . At follow-up, the prevalence of cognitive decline was lower among BL-ICD + (19.2 vs 37.1%, p = 0.025).
Conclusion: ICDs were associated with increased psychiatric burden at baseline and better cognitive prognosis. Most patients were still showing ICDs at the follow-up visit, suggesting ICD to be considered as a chronic, neuropsychiatric disorder.